PAM50 HER2-enriched phenotype as a predictor of early response to neoadjuvant lapatinib plus trastuzumab HER2-positive breast cancer: Survival results of the SOLTI-PAMELA study


Por: Pascual T, De Las Heras B, Martinez N, Oliveira M, Simon S, Lopez R, Cabrero I, Alarcon J, de Duenas E, Gimenez D, Cao M, Sanchez L, Murillo S, de Ceballos H, Cortes J, Cussac A, Prat A

Publicada: 1 may 2022 Ahead of Print: 1 may 2022
Resumen:

ISSN: 09237534





Annals Of Oncology
Editorial
OXFORD UNIV PRESS, GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND, Reino Unido
Tipo de documento: Article
Volumen: 33 Número:
Páginas: 168-168
WOS Id: 000792494100097

MÉTRICAS